Author:
Atzpodien Jens,Patzelt Tatjana,Reitz Martina
Reference225 articles.
1. Agarwala SS, Bahnson, RR, Wilson JW, Szumowski J, Ernstoff, MS (1995) Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma. A phase I study. Am J Clin Oncol 18: 211–215.
2. Alimov A, Li C, Gizatullin R, Fredriksson V, Sundelin B, Klein G, Zabarovsky E, Bergerheim U (1999) Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res 19: 3841–3846.
3. Atzpodien J, Kirchner H, Bergmann L (1999) 13 cis-retinoic acid, IFN-alpha, IL-2 and chemotherapy in advanced renal cell carcinoma: Results of a prospectively randomized trial of the German Cooperative Renal Carcinoma Immunotherapy Group (DGCIN). Proc Am Soc Clin Oncol: 19.
4. Atzpodien J, Kirchner H, Duensing S, Lopez HE, Franzke A, Buer J, Probst M, Anton P, Poliwoda H (1995a) Biochemotherapy of advanced metastatic renal-cell carcinoma: Results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol 13: 174–177.
5. Atzpodien J, Kirchner H, Franzke A, Wandert T, Probst M, Buer J, Duensing S, Ganser A (1997) Results of a randomized clinical trial comparing SC interleukin-2, SC alpha-2a-interferon, and IV bolus 5-fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma patients. Proc Am Soc Clin Oncol.